Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Yum! Brands, Inc. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B), while Yum! Brands, Inc. trades at $148.5 (market cap $40.03B). The key difference: Yum! Brands, Inc. is far larger — about 5.4× Spyre Therapeutics Inc. Common Stock's market cap, and Yum! Brands, Inc. pays a 2.05% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Yum! Brands, Inc. for 133 Days on average.
| SYRE | YUM | |
|---|---|---|
Market Cap | $7.35B | $40.03B |
Volume | 1,624,631 | 2,743,207 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $168.16 |
52-Week Low | $22.18 | $135.77 |
Typical Hold Time | 0 Days | 133 Days |
Enterprise Value | $6.35B | $51.63B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
YUM Brands trades at $147.06, up 0.21% with a bullish technical signal. The company shows strong fundamentals with 2025 revenue of $8.21B and net income of $1.56B, though Q4 2025 EPS missed expectations. Recent developments include the sale of Pizza Hut for approximately $1.5B and the launch of KFC's Open House concept. Analyst consensus is mixed with 39% buy ratings and a $170.44 price target, representing 16% upside potential from current levels.
YUM presents a compelling opportunity with improving cash flows and strategic brand focus, but faces risks from high debt levels and competitive pressures. The stock's current valuation appears reasonable with a P/E of 18.52, while technical indicators suggest near-term support at $145 with resistance at $148.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
